CRISPR Therapeutics AG $CRSP Shares Purchased by Tyche Wealth Partners LLC

Tyche Wealth Partners LLC increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 71.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 15,785 shares of the company’s stock after buying an additional 6,600 shares during the quarter. Tyche Wealth Partners LLC’s holdings in CRISPR Therapeutics were worth $768,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SVB Wealth LLC acquired a new stake in shares of CRISPR Therapeutics in the first quarter valued at approximately $25,000. Costello Asset Management INC purchased a new stake in CRISPR Therapeutics in the 1st quarter valued at $27,000. Quantbot Technologies LP boosted its stake in CRISPR Therapeutics by 272.4% during the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock worth $45,000 after purchasing an additional 978 shares during the period. NBC Securities Inc. grew its position in CRISPR Therapeutics by 156,300.0% during the 1st quarter. NBC Securities Inc. now owns 1,564 shares of the company’s stock worth $53,000 after purchasing an additional 1,563 shares during the last quarter. Finally, GF Fund Management CO. LTD. grew its position in CRISPR Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company’s stock worth $74,000 after purchasing an additional 394 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CRSP shares. Needham & Company LLC reiterated a “buy” rating and set a $81.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, July 8th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, September 23rd. Zacks Research raised CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. JMP Securities restated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Finally, Barclays lifted their price objective on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Ten equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $71.50.

Insider Activity at CRISPR Therapeutics

In related news, Director Simeon George purchased 989,812 shares of the stock in a transaction dated Wednesday, July 16th. The shares were acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the purchase, the director directly owned 1,730,179 shares in the company, valued at $90,021,213.37. This trade represents a 133.69% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Trading Up 3.6%

Shares of CRSP stock opened at $70.19 on Tuesday. The stock has a 50 day simple moving average of $57.82 and a 200-day simple moving average of $48.06. The company has a market cap of $6.38 billion, a price-to-earnings ratio of -12.93 and a beta of 1.84. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $73.95.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million for the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The company’s revenue for the quarter was up 72.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.49) earnings per share. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.